SEQUENCE LISTING

<110>	AGENT/REPRESENTATIVE: Greenlee, Winner and Sullivan, P.C. APPLICANT: Emory University CHAIKOF, Elliot L. CAZALIS, Chrystelle S. HALLER, Carolyn A.										
<120>	Thrombomodulin Conjugates										
<130>	11-04 wo										
<140> <141>	PCT/US TO BE ASSIGNED 2005-02-22										
<150> <151>	US 60/546,436 2004-02-20										
<160>	6										
<170>	PatentIn version 3.3										
<210> 1 <211> 459 <212> DNA <213> Artificial											
<220> <223> Synthetic construct											
<220> <221> <222>	CDS (8)(451)										
<400>	1 cc gac ccg tg	r ttc aga	מככ אאנ	tac	gag	tac	cad	tac	cad	ccc	49
ggacco	Asp Pro Cy	s Phe Arg	Ala Asr	Cys	ĞĨű	Tyr 10	ĞÎn	Cys	ĞÎñ	Pro	
ctg aa Leu As 15	ac caa act ag sn Gln Thr Se	c tac ctc r Tyr Leu 20	tgc gtc Cys Val	tgc Cys	gcc Ala 25	gag Glu	ggc Gly	ttc Phe	gcg Ala	ccc Pro 30	97
att co Ile Pr	cc cac gag co o His Glu Pro 35	g cac agg o His Arg	tgc cag Cys Glr	ctg Leu 40	ttt Phe	tgc Cys	aac Asn	cag Gln	act Thr 45	gcc Ala	145
tgt co Cys Pr	a gcc gac tg o Ala Asp Cy 50	c gac ccc s Asp Pro	aac acc Asn Thr 55	cag Gln	gct Ala	agc Ser	tgt Cys	gag Glu 60	tgc Cys	cct Pro	193
gaa go Glu Gl	oc tac atc ct ly Tyr Ile Le 65	g gac gac u Asp Asp	ggt tto Gly Phe 70	atc Ile	tgc Cys	acg Thr	gac Asp 75	atc Ile	gac Asp	gag Glu	241
tgc ga Cys Gl 80	aa aac ggc gg lu Asn Gly Gl)	c ttc tgc y Phe Cys 85	tcc ggg Ser Gly	gtg Val	tgc Cys	cac His 90	aac Asn	ctc Leu	ccc Pro	ggt Gly	289
acc tt Thr Ph 95	cc gag tgc at ne Glu Cys Il	c tgc ggg e Cys Gly 100	ccc gad Pro Asp	tcg Ser	gcc Ala 105	ctt Leu	gcc Ala	cgc Arg	cac His	att Ile 110	337
ggc ac Gly Th	cc gac tgt ga nr Asp Cys As 11	p Ser Gly	aag gto Lys Val	gac Asp 120	ggt Gly	ggc Gly	gac Asp	agc Ser	ggc Gly 125	tct Ser	385
ggc ga	ag ccc ccg cc	c agc ccg	acg ccd		tcc ge 1		ttg	act	cct	ccg	433

```
Gly Glu Pro Pro Pro Ser Pro Thr Pro Gly Ser Thr Leu Thr Pro Pro
gcc gtg ggg ggt atg taa tcggatcc
Ala val Gly Gly Met
145
<210>
<211>
        147
<212> PRT
<213>
        Artificial
<220>
<223>
       Synthetic Construct
<400> 2
Asp Pro Cys Phe Arg Ala Asn Cys Glu Tyr Gln Cys Gln Pro Leu Asn 1 10 15
Gln Thr Ser Tyr Leu Cys Val Cys Ala Glu Gly Phe Ala Pro Ile Pro
20 25 30
His Glu Pro His Arg Cys Gln Leu Phe Cys Asn Gln Thr Ala Cys Pro
45
Ala Asp Cys Asp Pro Asn Thr Gln Ala Ser Cys Glu Cys Pro Glu Gly 50 60
Tyr Ile Leu Asp Asp Gly Phe Ile Cys Thr Asp Ile Asp Glu Cys Glu 65 70 75 80
Asn Gly Gly Phe Cys Ser Gly Val Cys His Asn Leu Pro Gly Thr Phe 85 90 95
Glu Cys Ile Cys Gly Pro Asp Ser Ala Leu Ala Arg His Ile Gly Thr 100 \hspace{1.5cm} 105
Asp Cys Asp Ser Gly Lys Val Asp Gly Gly Asp Ser Gly Ser Gly Glu 115 120
Pro Pro Pro Ser Pro Thr Pro Gly Ser Thr Leu Thr Pro Pro Ala Val
130 135 140
Gly Gly Met
145
<210>
        3
        147
<211>
<212>
        PRT
<213>
       Artificial
<220>
<223>
       Synthetic construct
<220>
<221>
       MISC_FEATURE
```

459

```
<222> (40)..(40)
      Met-388-Leu substitution; position 40
<400> 3
Asp Pro Cys Phe Arg Ala Asn Cys Glu Tyr Gln Cys Gln Pro Leu Asn 1 10 15
Gln Thr Ser Tyr Leu Cys Val Cys Ala Glu Gly Phe Ala Pro Ile Pro
20 25 30
His Glu Pro His Arg Cys Gln Leu Phe Cys Asn Gln Thr Ala Cys Pro
35 40 45
Ala Asp Cys Asp Pro Asn Thr Gln Ala Ser Cys Glu Cys Pro Glu Gly 50 60
Tyr Ile Leu Asp Asp Gly Phe Ile Cys Thr Asp Ile Asp Glu Cys Glu 65 70 75
Asn Gly Gly Phe Cys Ser Gly Val Cys His Asn Leu Pro Gly Thr Phe
85 90 95
Glu Cys Ile Cys Gly Pro Asp Ser Ala Leu Ala Arg His Ile Gly Thr
100 105 110
Asp Cys Asp Ser Gly Lys Val Asp Gly Gly Asp Ser Gly Ser Gly Glu
115 120
Pro Pro Pro Ser Pro Thr Pro Gly Ser Thr Leu Thr Pro Pro Ala Val
130 135 140
Gly Gly Met
145
<210>
<211>
<212>
        575
        PRT
<213>
       Homo sapiens
<400> 4
```

Met Leu Gly Val Leu Val Leu Gly Ala Leu Ala Leu Ala Gly Leu Gly 1 10 15

Phe Pro Ala Pro Ala Glu Pro Gln Pro Gly Gly Ser Gln Cys Val Glu 20 25 30

His Asp Cys Phe Ala Leu Tyr Pro Gly Pro Ala Thr Phe Leu Asn Ala 35 40 45

Ser Gln Ile Cys Asp Gly Leu Arg Gly His Leu Met Thr Val Arg Ser 50 60

Ser Val Ala Ala Asp Val Ile Ser Leu Leu Leu Asn Gly Asp Gly Gly Page 3 65

Val Gly Arg Arg Leu Trp Ile Gly Leu Gln Leu Pro Pro Gly Cys 85 90 95 Gly Asp Pro Lys Arg Leu Gly Pro Leu Arg Gly Phe Gln Trp Val Thr 100 105 110Gly Asp Asn Asn Thr Ser Tyr Ser Arg Trp Ala Arg Leu Asp Leu Asn 115 120 125 Gly Ala Pro Leu Cys Gly Pro Leu Cys Val Ala Val Ser Ala Ala Glu 130 135 140 Ala Thr Val Pro Ser Glu Pro Ile Trp Glu Glu Gln Gln Cys Glu Val 145 150 160 Lys Ala Asp Gly Phe Leu Cys Glu Phe His Phe Pro Ala Thr Cys Arg 165 170 175 Pro Leu Ala Val Glu Pro Gly Ala Ala Ala Ala Ala Val Ser Ile Thr 180 185 190 Tyr Gly Thr Pro Phe Ala Ala Arg Gly Ala Asp Phe Gln Ala Leu Pro 195 205 val Gly Ser Ser Ala Ala Val Ala Pro Leu Gly Leu Gln Leu Met Cys 210 220 Thr Ala Pro Pro Gly Ala Val Gln Gly His Trp Ala Arg Glu Ala Pro 225 230 235 240 Gly Ala Trp Asp Cys Ser Val Glu Asn Gly Gly Cys Glu His Ala Cys 245 250 255 Asn Ala Ile Pro Gly Ala Pro Arg Cys Gln Cys Pro Ala Gly Ala Ala 260 265 270 Leu Gln Ala Asp Gly Arg Ser Cys Thr Ala Ser Ala Thr Gln Ser Cys 275 280 285 Asn Asp Leu Cys Glu His Phe Cys Val Pro Asn Pro Asp Gln Pro Gly 290 295 300 Ser Tyr Ser Cys Met Cys Glu Thr Gly Tyr Arg Leu Ala Ala Asp Gln 305 310 315 His Arg Cys Glu Asp Val Asp Asp Cys Ile Leu Glu Pro Ser Pro Cys 325 330 335 Pro Gln Arg Cys Val Asn Thr Gln Gly Gly Phe Glu Cys His Cys Tyr 340 345 350

Page 4

Pro Asn Tyr Asp Leu Val Asp Gly Glu Cys Val Glu Pro Val Asp Pro 355 360 365 Cys Phe Arg Ala Asn Cys Glu Tyr Gln Cys Gln Pro Leu Asn Gln Thr 370 375 380 Ser Tyr Leu Cys Val Cys Ala Glu Gly Phe Ala Pro Ile Pro His Glu 385 390 395 400 Pro His Arg Cys Gln Met Phe Cys Asn Gln Thr Ala Cys Pro Ala Asp 405 410 415 Cys Asp Pro Asn Thr Gln Ala Ser Cys Glu Cys Pro Glu Gly Tyr Ile 420 425 430 Leu Asp Asp Gly Phe Ile Cys Thr Asp Ile Asp Glu Cys Glu Asn Gly
435
440
445 Gly Phe Cys Ser Gly Val Cys His Asn Leu Pro Gly Thr Phe Glu Cys 450 460 Ile Cys Gly Pro Asp Ser Ala Leu Ala Arg His Ile Gly Thr Asp Cys 480 Asp Ser Gly Lys Val Asp Gly Gly Asp Ser Gly Ser Gly Glu Pro Pro 485 490 495 Pro Ser Pro Thr Pro Gly Ser Thr Leu Thr Pro Pro Ala Val Gly Leu 500 505 510 Val His Ser Gly Leu Leu Ile Gly Ile Ser Ile Ala Ser Leu Cys Leu 515 520 525 Val Val Ala Leu Leu Ala Leu Leu Cys His Leu Arg Lys Lys Gln Gly 530 540 Ala Ala Arg Ala Lys Met Glu Tyr Lys Cys Ala Ala Pro Ser Lys Glu 545 550 560

Val Val Leu Gln His Val Arg Thr Glu Arg Thr Pro Gln Arg Leu 565 570 575


<210> 5
<211> 21
<212> DNA
<213> Artificial
<220>
<223> Synthetic construct
<400> 5
taccctaact acgacctggt g

```
<210> 6
<211> 18
<212> DNA
<213> Artificial

<220>
<223> Synthetic construct

<400> 6
tatgagcaag cccgaatg
```

18



PLEASE ACKNOWLEDGE RECEIPT OF THE FOLLOWING:

- 1. Certificate of Mailing by Express Mail 1 page
- 2. PCT International Application Transmittal Letter 1 page
- 3. PCT Request in paper form 5 pages.
- 4. Fee Calculation page in paper form 1 page
- Specification excluding sequence listing (description 27 pages; claims 5 pages; abstract 1 page) 33 pages
- 6. 4 sheets of drawings
- 7. Sequence listing; paper 6 pages
- 8. Sequence listing; Computer Readable Form/CRF 1 diskette
- 9. Statement under 37 CFR 1.821-824 1 page
- 10. PCT-Safe file on diskette (11-04WO.zip; 11-04WO.log)
- 11. Check in the amount of \$2,589.00

Attorney Docket No. 11-04 WO

SJP/can: 2/22/05

Express Mail Receipt No.: EV 663 225 151 US

ENT'D MAR 1 0 2005 EV663225151US